CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms

Figures & data

Table 1. Frequency of driver mutations in BCR-ABL1-negative MPNs.

	PV (n = 176) (%)	ET (n = 214) (%)	PMF (n = 49) (%)	MPN (n = 439) (%)
JAK2 V617F	167 (94.9)	131 (61.2)	31 (62)	329 (74.9)
CALR mutations	–	46 (21.5)	8 (16.3)	54 (12.3)
Type 1 mutation	–	19 (41.3)	1 (12.5)	20 (37)
Type 2 mutation	–	17 (37)	7 (87.5)	24 (44.4)
MPL mutation	–	6 (2.8)	3 (6.1)	9 (2.1)
Triple negative	9 (5.1)	31 (14.5)	7 (14.3)	47 (10.7)

Table 2. Main clinical and hematological features of 208 patients with ET stratified by mutational status.

	JAK2V617F^1	CALR^2	Triple negative^3	P^1vs.2 value	P^1vs.3 value	P^2vs.3 value
N	131	46	31
Sex (male/female)	51/80 (40%/60%)	20/26 (44%/56%)	10/21 (32%/68%)	0.604	0.542	0.35
Age onset (years)	64 (54–75)	59 (47–69)	48 (32–66)	0.168	0.012	0.212
Leucocytes (×10^9/L)	11.3 (9.2–15.2)	8.3 (7.3–10.3)	9.6 (7.7–12.1)	<0.001	<0.001	0.237
Haemoglobin (g/dL)	14 (12.2–15.4)	12.6 (11.6–14.0)	12.8 (11.3–14.3)	<0.001	0.009	0.79
Platelets (×10^9/L)	885 (654–1123)	1028 (889–1509)	860 (720–1200)	<0.001	0.49	0.009

Statistically significant values (P < 0.05) are shown in bold.

Table 3. Main clinical and hematological features of 46 patients with PMF stratified by mutational status.

	JAK617F^1	CALR^2	Triple negative^3	P^1vs.2 value	P^1vs.3 value	P^2vs.3 value
N	31	8	7
Sex (male/female)	13/18 (42%/58%)	03/05 (38%–62%)	07/00 (100%–0%)	–	–	–
Age onset (years)	64 (57–76)	65 (51–72)	58 (57–76)	0.93	0.699	0.855
Leucocytes (×10^9/L)	17 (8.2–29)	11.2 (3.9–19)	12.9 (2.9–32)	0.114	0.374	0.698
Haemoglobin (g/dL)	11 (9.5–13)	9.4 (7.5–13.2)	9.3 (8.4–11.3)	0.342	0.247	0.948
Platelets (×10^9/L)	276 (145–505)	529.5 (199–951)	80 (54–112)	0.142	0.009	<0.001

Statistically significant values (P < 0.05) are shown in bold.